Cabaletta Bio
A clinical-stage biotech company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases.
Cabaletta's CABA platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in systemic lupus erythematosus and myositis; and the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis.
The expanding CABA platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases.
Latest Cabaletta Bio News & Features
22 August 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze